NK Cell Mediated Immunity Clinical Trial
Official title:
Effect of Autologous NK Cell Immunotherapy on Advanced Lung Adenocarcinoma With EGFR Mutation: a Preliminary Clinical Study
This study was attempted to investigate the efficiency of NK cells immunotherapy on non-small cell lung cancer with and without EGFR mutation, and evaluated response rate (RR) and the progression-free survival (PFS).
Investigators will enrolle 100 patients who met the enrollment criteria. 50 patients were clinically confirmed EGFR mutation positive. They were divided into two groups (group A and group C according to if accepted NK therapy) in accordance with the principles of randomized. The rest 50 patients which were EGFR mutation negative were also divided into two groups (group B and group D) in accordance with the principles of randomized to be paired respectively with group A and group C. Comparison of lymphocyte number, serum tumor related biomarkers, circulating Tumor Cell (CTC), KPS and survival curves was carried out before after NK cell immunotherapy. The safety and short-term effects were evaluated followed by the median PDA, response rate assessment. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04377113 -
Cellular Immunity and Renal Cell Cancer
|
||
| Not yet recruiting |
NCT03948828 -
Clinical Study of NK Cells in the Treatment of Severe Endometriosis
|
Phase 1 | |
| Not yet recruiting |
NCT03554889 -
Immunotherapy of Advanced Cancer Using a Combination Nimotuzumab and NK Cells
|
Phase 1 |